SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies informs about press release

06 Jun 2024 Evaluate

Indoco Remedies has informed that it enclosed a Press release regarding receipt of tentative approval from USFDA, for the Company’s Abbreviated New Drug Application for Canagliflozin and Metformin Hydrochloride Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg, a generic equivalent of Invokamet® Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg. 

The above information is a part of company’s filings submitted to BSE.

Indoco Remedies Share Price

251.90 4.05 (1.63%)
15-Jul-2026 09:24 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1950.70
Dr. Reddys Labs. 1238.30
Cipla 1445.00
Zydus Lifesciences 1137.60
Lupin 2488.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: